Back to Peptides

GHRP-6

Growth Factors & Muscle Building

GHRP-6 is a growth hormone-releasing hexapeptide that mimics ghrelin to stimulate the pituitary gland. It is studied in both preclinical and clinical settings for its GH-promoting and appetite-stimulating properties; commonly stacked with CJC-1295 for synergistic GH release.

Reconstitute
2.5 mL BAC + 5mg vial
20 mcg/unit
Daily Range
100–300 mcg Subcutaneous (SQ)
Up to twice daily
Standard Dose
200 mcg
Cycle
4–8 weeks
then reassess
GHRP-6Growth HormoneGhrelin receptorBody compositionSecretagogue

Dosing & Reconstitution Guide

In clinical research, doses range from 100–300 μg per injection, typically 2–3x daily. These are investigational values and not approved for therapeutic use.

Standard / Gradual Approach

2mg Vialstandard
PhaseDoseVolume
Weeks 1–2100 mcg15 units (0.15 mL)
Weeks 3–4200 mcg30 units (0.30 mL)
Weeks 5–12300 mcg45 units (0.45 mL)

Standard / Gradual Approach

10mg Vialstandard
PhaseDoseVolume
Weeks 1–2100 mcg3 units (0.03 mL)
Weeks 3–4200 mcg6 units (0.06 mL)
Weeks 5–12300 mcg9 units (0.09 mL)

Protocol Summary

Subcutaneous (SQ): Up to twice daily · Dose range 100300 mcg with gradual titration
Intranasal: Up to twice daily · Dose range 2050 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Use 8–12 weeks followed by 4-week break. Administer before meals or at night to optimize GH secretion.

Intranasal

Administer 1–2x daily with enhanced intranasal formulation. Use same cycling strategy as injection.

🧪 Quick Start

Vial Size
5 mg
BAC Water
3 mL
Concentration
2 mcg/unit

Potential Benefits & Use Cases

GHRP-6 is a research compound not approved by the FDA or any regulatory body for medical use.
Produces consistent GH and IGF-1 elevation supporting anabolic processes (human trial)
May enhance lean muscle mass, strength, and tissue repair through IGF-1 elevation (preclinical)
Pronounced ghrelin-mimetic appetite stimulation within 20–30 minutes post-injection — useful for cachexia (human trial)
Increases stage 2 sleep duration (270 minutes vs 245 minutes placebo) without major REM disruption (human trial)
Clinical data Strong preclinical Limited data

Mechanism of Action

Activates ghrelin receptor (GHS-R1a)
Stimulates release of growth hormone from the anterior pituitary
Enhances appetite and anabolic signaling via GH axis

Lifestyle & Optimization

timing

Administer on empty stomach (2–3 hours post-meal). GH peaks during deep sleep.

diet

Protein-forward diet. Mind appetite stimulation if fat loss is the goal.

exercise

Resistance and aerobic training.

sleep

Prioritize sleep — GH peaks during deep sleep.

Side Effects & Safety

Common Side Effects

Transient ACTH and cortisol elevation post-injection (clinically insignificant) (human trial)

🧮 Dose Calculator

Concentration
20.0
mcg/unit
Draw Volume
25
units (0.250 mL)
For a 500 mcg dose, draw 25 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
High systemic bioavailability via subcutaneous injection
Oral Administration
Poor oral bioavailability
Intranasal
Moderate with enhanced delivery carriers
Half-Life
Approximately 30 minutes
Degradation
Metabolized in liver and kidneys
Tissue Specificity
Acts on GH receptor pathways, muscle, and adipose tissue
⚗️

Peptide Details

Molecular Weight
873.01
Formula
C46H56N12O6
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
⚖️

Legal Status & Regulatory

RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days with bacteriostatic water